Synthesis of L-tricholomic acid analogues and pharmacological characterization at ionotropic glutamate receptors by L. Tamborini et al.
FULL PAPER    
 
 
 
 
 
Synthesis of L-Tricholomic Acid Analogues and Pharmacological 
Characterization at Ionotropic Glutamate Receptors 
Lucia Tamborini,[a] Federica Mastronardi,[a] Leonardo Lo Presti,[b] Birgitte Nielsen,[c] Carlo De Micheli,[a] 
Paola Conti[a] and Andrea Pinto*[d] 
 
Abstract: The synthesis of analogues of the natural compound L-
tricholomic acid and of its threo diastereoisomer was 
accomplished in order to explore their affinity for glutamate 
ionotropic receptors. In this study, fourteen new unnatural amino 
acids, characterized by a 3-hydroxy-∆2-isoxazoline or 3-hydroxy-
∆2-pyrazoline-skeleton, were obtained exploiting, as key reaction, a 
1,3-dipolar cycloaddition or an intramolecular cyclization.   
Introduction 
L-Tricholomic acid [Figure 1] is a natural compound extracted 
from the poisonous mushrooms Tricholoma muscarium, Amanita 
strobiliformis and Ustilago maydis.[1-4] It is a partially rigidified 
analogue of the endogenous ligand L-glutamate (L-Glu), in which 
the distal carboxylic group is bioisosterically replaced by the 3-
hydroxy-isoxazoline ring. L-Glu is the main excitatory 
neurotransmitter in the central nervous system (CNS), where it is 
involved in the modulation of many physiological processes such 
as learning, memory, and synaptic plasticity.[5] On the other hand, 
L-Glu plays a crucial role in acute and chronic neurodegenerative 
diseases (i.e., cerebral ischemia, traumatic brain injury, spinal 
injury, epilepsy, ALS, Parkinson’s, Alzheimer’s and Huntington’s 
diseases).[6] Once released into the synaptic cleft, L-Glu operates 
through through both ionotropic and metabotropic L-Glu receptors 
(iGluRs and mGluRs, respectively).[7]  
We previously prepared L-tricholomic acid together with its three 
non-natural isomers, and we demonstrated that L-tricholomic acid 
is an agonist at the ionotropic glutamate receptors AMPA and KA 
(IC50 = 0.95 μM and 0.29 μM, respectively), whereas its D-
enantiomer interacts selectively with the NMDA receptors (Ki = 
0.67 μM) and both the L-threo and D-threo diastereoisomers are 
weak and non-selective iGluR ligands.[8] 
It is well known that the homologation of the amino acidic chain of 
glutamatergic ligands could lead to a modification of the selectivity 
profile towards different Glu receptors and, interestingly, also to a 
shift of the pharmacological profile from an agonist to a partial 
agonist or even an antagonist.[9] Our interest in the design of 
selective ligands for glutamate receptors arises from the fact that 
the glutamatergic system has proved to be an important target for 
the therapy of acute and chronic diseases of the mammalian 
central nervous system. The availability of highly selective ligands 
for the different receptor subtypes represents a primary target to 
understand the physiological role played by the different subtypes 
and to design new neuroprotective agents with reduced side 
effects. Therefore, we decided to synthesize new 
enantiomerically pure amino acids 1-4 (Figure 1), which represent 
higher homologues of the model compound tricholomic acid and 
its threo diastereoisomer. Compounds (αS,5S)-3a-c, (αS,5R)-4a-
c (Figure 1) are also characterized by an increased molecular 
complexity obtained through the insertion of a bulky phenyl ring in 
the 3-position of the isoxazoline core, functionalized in the ortho, 
meta or para position with the second acidic function, i.e., the 
carboxylic acid. Increasing the molecular complexity could lead to 
an increase of the binding affinity for one glutamate receptor 
subtype, thus obtaining more selective ligands. 
Similarly, an increase of the molecular complexity was obtained 
in compounds (αS*,5R*)-5a, (αS*,5S*)-5b, (αS*,5R*)-6a and 
(αS*,5S*)-6b, in which the isoxazoline ring was substituted with 
a pyrazoline ring bearing a benzyl group at the N1.   
Very recently, this strategy led us to the identification of novel 
subtype selective NMDA receptor antagonists.[10] In order to 
facilitate the synthetic pathway, these amino acids have been 
initially synthesized as racemates starting from D,L-serine, with 
the purpose of preparing and testing the single enantiomers only 
if any interesting biological activity would be observed. The ortho-
substituted derivative resulted to be unstable in bases because 
it underwent intramolecular lactamization due to the reaction of 
the aromatic carboxylate with the N2 of the pyrazoline, forming a 
stable six-membered ring.  
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Results and Discussion 
To synthesize the target compounds 1-2, we exploited the 1,3-
dipolar cycloaddition reaction using the racemic dipolarophile (±)-
8 and bromoformonitrile oxide, generated in situ by treating its 
precursor dibromoformaldoxime 7 with a base, with the idea to 
separate the single enantiomers of the formed cycloadducts by 
semi-preparative chiral HPLC (Scheme 1). When the reaction 
was complete, the two diastereoisomers (±)-9 and (±)-10 were 
efficiently separated by flash chromatography. The relative 
configuration of the new cycloadducts was initially assigned by 
comparison of the chemical shifts and the coupling constants with 
the ones of some previously reported analogues.[11] In particular, 
the signals corresponding to the two hydrogen atoms in 3’-
position were peculiar. The outcome of the cycloaddition reaction, 
which gave as the major products the 5-substituted isoxazolines, 
is in line with theoretical prediction on the basis of the Frontier 
orbital theory where the dominant interaction involves the LUMO 
of the 1,3-dipole and the HOMO of the dipolarophile.[12] 
 
 
 
Scheme 1. Reagents and conditions: a) NaHCO3, EtOAc, rt, 48 h. 
In order to separate the two pairs of enantiomers (+)-9/()-9 and 
(+)-10/()-10 by chiral HPLC, a number of different stationary 
phases in combination with various eluent solutions and flow rates 
have been explored. The best conditions for the separation of the 
two racemic mixture were obtained using a tris-(3,5-
dimethylphenyl)carbamoyl amylose as chiral stationary phase. 
The separation of the enantiomers (+)-9/()-9 and (+)-10/()-10 
was then efficiently performed, obtaining the single enantiomers 
in 99% ee.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound (+)-9 has been crystallized using a mixture EtOAc/n-
hexane and, due to the anomalous scattering of the bromine atom, 
its absolute configuration was unequivocally determined by 
single-crystal X-ray diffraction analysis and resulted to be (+)-
(αS,5R)-9, confirming our initial speculation on the basis of the 1H 
NMR. Figure 2 shows the asymmetric unit of compound (+)-9 with 
the atom-numbering scheme and a photograph of the crystal used 
for the analysis.  
Figure 2. Diffraction-quality crystal and perspective view of the molecular 
structure of (+)-9 at room temperature, with the atom numbering scheme. 
Thermal ellipsoids are drawn at the 30 % probability level. 
 
Also enantiomer ()-10 was successfully crystallized using a 1:1 
mixture dichloromethane/n-hexane and its absolute configuration 
was determined by single-crystal X-ray diffraction analysis and 
resulted to be ()-(αS,5S)-10 (Figure 3). CCDC 1560014 for [(+)-
9] and 1560013 for [()-10] contain the full supplementary 
crystallographic data for this work. The latter can be obtained free 
of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Finally, compounds (αS,5R)-9, (αR,5S)-9, (αR,5R)-10 and 
(αS,5S)-10 were converted into the desired amino acids (αS,5R)-
1, (αR,5S)-1, (αR,5R)-2 and (αS,5S)-2, respectively, by alkaline 
hydrolysis of the ester function, replacement of the 3-Br 
substituent with a hydroxyl group through a nucleophilic 
substitution reaction and standard Boc-deprotection with 
trifluoacetic acid (Scheme 2).  
 
Figure 1. Structures of the model compound L-tricholomic acid and target compounds. 
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Figure 3. Diffraction-quality crystal and the asymmetric unit of compound ()-
10 at room temperature, with the atom numbering scheme. Thermal ellipsoids 
are drawn at the 30 % probability level. 
 
 
 
 
Scheme 2. Reagents and conditions: a) 0.5N NaOH, dioxane, rt; b) 1N NaOH, 
65 °C; c) 30% TFA in CH2Cl2, rt. 
The synthesis of compounds (αS,5S)-3a-c and (αS,5R)-4a-c was 
accomplished exploiting the 1,3-dipolar cycloaddition of the 
suitable nitrile oxide, generated in situ by treatment of its 
corresponding stable chloro oxime precursor 12-14 with a base, 
with (S)-3-(tert-butoxycarbonyl)-2,2-dimethyl-4-vinyloxazolidine 
(S)-11 (Scheme 3), prepared starting from D-serine following a 
literature procedure.[8] Choro oximes 12, 13 and 14 were prepared 
starting from the corresponding aldehydes following a reported 
protocol.[13] The acetonide of intermediates 15-17 was removed 
by treatment with a 1:5 solution H2O/AcOH,[14] and, at this stage, 
it was possible to separate the couple of diasteroisomers by flash 
column chromatography. The primary alcohol of the isolated 
diastereoisomers was oxidized to carboxylic acid with PDC in 
DMF and in turn converted into the final amino acids (αS,5S)-3a-
c and (αS,5R)-4a-c using standard deprotection conditions 
(Scheme 3).The relative configuration of derivatives 3a/4a, 3b/4b, 
and 3c/4c was assigned by comparing their 1H NMR 
spectroscopic signals with the signals of the model compound L-
tricholomic acid.  
Finally, the 3-hydroxy-pyrazoline derivatives were synthesized 
through a condensation/intramolecular cyclization between 
hydrazine and the α,β-unsatured ester (±)-20, in turn obtained 
starting from D,L-serine.[15a] The key intermediate (±)-21 was 
obtained as a 1:1 mixture of two racemic diasteroisomers with 
relative configuration (αS*,5S*) and (αS*,5R*), inseparable at this 
stage. Treatment of intermediate (±)-21 with methyl-3-
(bromomethyl)benzoate or methyl-4-(bromomethyl)benzoate in 
presence of K2CO3 under microwave irradiation yielded 
intermediates (±)-22a/23a and (±)-22b/23b, respectively 
(Scheme 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: a) NaHCO3, EtOAc, rt; b) 1:5 mixture 
H2O/AcOH; c) PDC, DMF; d) 0.5N NaOH; e) 30% TFA in CH2Cl2. 
 
The couples of diastereoisomers (±)-22a/23a and (±)-22b/23b 
were separated by column chromatography after conversion into 
the corresponding methyl esters (±)-24a,b and (±)-25a,b. The 
assignment of the relative configuration to the diastereoisomers 
was based on the comparison of the 1H NMR spectra of each 
diastereoisomer with that of previously reported analogues, 
whose relative configuration was unambiguously assigned by X-
ray analysis.[15b] The final amino acids (αS*,5R*)-5a, (αS*,5S*)-5b, 
(αS*,5R*)-6a and (αS*,5S*)-6b were obtained after alkaline 
hydrolysis of the methyl esters followed by cleavage of the Cbz 
protecting group with hydrobromic acid in a solution of acetic acid.  
Binding affinities of the synthesized amino acids were determined 
at native AMPA, KA, and NMDA receptors (rat synaptosomes). 
The data reported in Table 1 show that the carbon homologation 
carried out on the model compound tricholomic acid and its 
unnatural isomers has produced some changes in the affinity 
profile for iGluRs. In fact, while amino acid (αR,5S)-1 is a ligand 
endowed with a good affinity (Ki = 6.0 μM) and selectivity for the 
NMDA receptors, its enantiomer is a non-selective ligand, 
characterized by low affinity for both the KA and NMDA receptors.  
Concerning stereoisomers (αR,5R)-2 and (αS,5S)-2, we 
observed that while amino acid (αR,5R)-2 possesses affinity for 
both the AMPA (Ki = 12 μM) and NMDA (Ki = 6.2 μM) receptors, 
compound (αS,5S)-2 showes no affinity for any of the iGluRs. The 
obtained data parallel the results observed for the majority of the 
NMDA antagonists reported in the literature, in which the 
interaction with NMDA receptor complex is usually 
enantioselective and resides in the (R)-enantiomer. 
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Binding data showed for all the other compounds a general 
decrease in affinity. None of the amino acids, 3a-c and 4a-c, 
revealed affinity for AMPA or KA receptors at concentration up to 
100 µM. Replacing the isoxazoline ring with the pyrazoline 
nucleus did not improve the binding affinity: among derivatives 
5a,b and 6a,b only (αS*,5R*)-5a is able to interact with AMPA or 
KA receptors with affinities in the mid-micromolar range. Notably, 
in this case the binding preference depends on the relative 
stereochemistry since (αS*,5R*)-5a is a non-selective AMPA/KA 
ligand whereas its diasteroisomer (αS*,5S*)-5b is devoid of any 
affinity for iGluRs. 
Conclusions 
We have synthesized a series of analogues of the natural 
compound L-tricholomic acid in the attempt to identify potential 
selective ligands for iGluR subtypes. The rationale was based on 
the use of classical medicinal chemistry strategies, widely applied 
in the design of glutamatergic ligands, i.e., homologation of the 
amino acidic chain and increase of the molecular complexity. The 
key step for the synthesis of compounds 1-4 was a cycloaddition 
reaction performed in good yields starting from the appropriate 
dipoles and dipolarophiles. Compounds 1 and 2 have been 
obtained as single enantiomers by exploiting a semi-preparative 
chiral HPLC separation on the protected precursors, whereas 
enantiomerically pure 3a-c and 4a-c have been synthesised 
starting from the chiral dipolarophile. The absolute 
stereochemistry for compounds 1 and 2 has been unequivocally 
assigned by X-ray crystallography of the protected precursors, 
whereas, for all the other amino acids the configuration was 
deduced by comparison of the 1H NMR spectra. Unfortunately, 
pharmacological investigation at native iGluRs did not highlight 
any ligand endowed with a worth noting affinity or selectivity for a 
specific receptor. We can speculate that the distance between the 
α-amino acidic group and the distal carboxylate may not be 
optimal for the interaction with the residues of the binding cavity. 
Unfortunately, also in the series of amino acids 5a,b and 6a,b we 
did not observe the expected increase of potency associated to 
an increased molecular complexity. 
 
 
 
 
Table 1. Receptor binding affinities at native iGluRs (rat synaptosomes)[a]  
Compound [3H]AMPA 
IC50 (μM) 
[3H]KAIN  
IC50 (μM) 
[3H]CGP39653  
Ki (μM) 
(αS,5R)-1 > 100 74 [4.13±0.01] 18 [4.74±0.03] 
(αR,5S)-1 > 100 > 100 6.0 [5.22±0.03] 
(αR,5R)-2  12 [4.96±0.15] > 100 6.2 [5.21±0.03] 
(αS,5S)-2 > 100 > 100 > 100 
(αS,5S)-3a > 100 > 100 > 100 
(αS,5R)-4a > 100 > 100 > 100 
(αS,5S)-3b > 100 > 100 > 100 
(αS,5R)-4b > 100 > 100 > 100 
(αS,5S)-3c > 100 > 100 > 100 
(αS,5R)-4c > 100 > 100 > 100 
(αS*,5R*)-5a 83 [4.08±0.02] 22 [4.67±0.09] > 100 
(αS*,5S*)-5b > 100 > 100 > 100 
(αS*,5R*)-6a > 100 > 100 > 100 
(αS*,5S*)-6b > 100 > 100 > 100 
L-tricholomic 
acid 
0.95 [6.02±0.01] 0.29 [6.55±0.06] 41 [4.40±0.07] 
[a] Data are given as mean [mean pIC50 ± SEM or mean pKi ± SEM] of three 
independent experiments 
 
Supporting Information Summary 
All the experimental procedures, compound characterizations, X-
ray diffraction analyses, binding assays are available in the 
Supporting Information. 
Scheme 4. a) Methyl-3-(bromomethyl)benzoate or methyl-4-(bromomethyl)benzoate, K2CO3, NaI, CH3CN, 85 °C, mw; b) PPTS, MeOH, H2O; c) K2CO3, MeOH; 
d) 0.5N NaOH, dioxane; e) 33% HBr in AcOH. 
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